Receive an MDS Diagnosis or Second Opinion at Moffitt Cancer Center in Tampa, FL
An MDS diagnosis can be highly complex, with subtle chromosomal differences indicating different syndromes and classifications. At Moffitt Cancer Center in Tampa, Florida, we have extensive experience in diagnosing and treating the full range of myelodysplastic syndromes, from the more common types to the seldom-seen diagnoses. Moffitt is not only a high-volume cancer center based on patient volume, but also home to one of the most robust and sophisticated malignant hematology programs in the nation.
Moffitt’s malignant hematology team understands that the key to successful myelodysplastic syndrome treatment lies in the ability to establish a proper MDS diagnosis. Each syndrome is highly unique, and treatment is dependent on the molecular and chromosomal analysis that occurs throughout the evaluation process. Our highly advanced diagnostic approach combines the expertise of numerous disciplines, including:
- Hematology
- Pathology
- Molecular biology
- Immunology
- Cytogenetics
Once an MDS diagnosis is established, our experienced physicians work as a collaborative group to guide each patient’s individualized treatment. Our treatment protocols are integrated with those of the Blood and Marrow Transplantation Program, and we have capabilities for both inpatient and outpatient chemotherapy administration at several locations throughout Tampa. Depending on the specifics of a patient’s MDS diagnosis, we may also be able to recommend one of our advanced clinical trials as another potential treatment option.
We welcome patients who do not yet have a confirmed MDS diagnosis, as well as those who have been diagnosed with a myelodysplastic syndrome and are seeking a second opinion from a Tampa, FL, area specialist. Referrals are never required at Moffitt. To schedule an appointment, call 1-888-663-3488 or submit a new patient registration form online.
Myelodysplastic Syndromes (MDS)
- Adrenal Cancer
- Anal Cancer
- Appendiceal (Appendix) Cancer
- Astrocytoma
- Basal Cell Carcinoma
- Bladder Cancer
- Bone Metastasis
- Brain Cancer
- Brain Tumor
- Breast Cancer
- Cervical Cancer
- Cholangiocarcinoma (Bile Duct Cancer)
- Colon Cancer
- Colorectal Cancer
- Cutaneous T-Cell Lymphoma
- Ductal Carcinoma In Situ
- Endometrial (Uterine) Cancer
- Esophageal Cancer
- Gallbladder Cancer
- Gastrointestinal Carcinoid Tumor
- GIST (Gastrointestinal Stromal Tumor)
- Glioblastoma
- Head and Neck Cancer
- HER2 Positive Breast Cancer
- Hodgkin Lymphoma
- Inflammatory Breast Cancer
- Invasive Ductal Carcinoma
- Kidney (Renal Cell) Cancer
- Leukemia
- Liver (Hepatocellular) Cancer
- Low-Grade Glioma
-
Lung Cancer
- Signs and Symptoms
- Diagnosis
- Treatment
- FAQs
- Lung Cancer Early Detection Center
- Lung Cancer Screening and Surveillance Program
- Lung Nodules
- Lung Surveillance Clinic
- Metastatic Lung Cancer
- Recurrence
- Survival Rate
- Your Lung Cancer Specialists
- Lung and Thoracic Tumor Education (LATTE)
- Thoracic Clinic Updates
- Insurance & Financial Information
- Lymphomas (Hodgkin and Non-Hodgkin)
- Melanoma
- Meningioma
- Merkel Cell Carcinoma
- Mesothelioma
- Metastatic Breast Cancer
- Multiple Myeloma-Plasma Cell Tumor
- Myelodysplastic Syndromes (MDS)
- Neuroendocrine Tumor
- Neurofibromatosis
- Non-Hodgkin Lymphoma
- Oral Cavity (Mouth) Cancer
- Oral Cavity or Throat Cancer
- Osteosarcoma
- Ovarian Cancer
- Pancoast Tumor
- Pancreatic Cancer
- Penile Cancer
- Pituitary Adenoma
- Prostate Cancer
- Rectal Cancer
- Sarcoma
- Skin Cancer (Nonmelanoma)
- Skull Base Tumors
- Small Intestine Cancer
- Spinal Tumor
- Squamous Cell Carcinoma
- Stomach (Gastric) Cancer
- Testicular Cancer
- Throat Cancer
- Thymoma
- Thyroid Cancer
- Tongue Cancer
- Tracheal Cancer
- Triple Negative Breast Cancer
- Vaginal Cancer
- Vulvar Cancer